Conclusions
The single bedtime dose of ON-SXB demonstrated clinically meaningful improvements in measures of EDS and DNS as well as overall condition compared to placebo in both the NT1 and NT2 subgroups across all doses evaluated (6, 7.5, and 9 g) in this post hoc analysis. In contrast to the twice-nightly oxybate formulations, ON-SXB does not disrupt or fragment sleep, and is less burdensome for patients as they can avoid the middle-of-the-night dose, which is particularly relevant given the potential chronic need for pharmacotherapy.